Introduction
Endothelin-1 (ET-1) was first identified in 1988 as an endothelial cell-derived peptide, with the greatest vasoconstrictor potency of any known endogenous compound. After over 22 000 publications dealing with endothelins, it is apparent that ET-1 exerts multiple biologic effects, including regulation of vascular tone, renal sodium and water excretion, cell growth and proliferation, extracellular matrix accumulation and others. Such biologic complexity is due to several factors that are mentioned below. First, ET-1 is produced by, and binds to, almost every cell type in the body. Second, the two mammalian endothelin receptors [endothelin A (ETA) and endothelin B (ETB)] can mediate different biologic effects within the same cell as well as between different cell types. Third, ET-1 functions primarily in an autocrine or paracrine manner (it is mainly secreted abluminally), permitting localized microenvironmental effects. Fourth, a large variety of factors modulate ET-1 production, including vasoactive mediators, cytokines, growth factors, inflammatory substances and others (Fig. 1) . Fifth, the biologic effects of ET-1 can differ depending upon the amount of ET-1 present. This review focuses on the role of ET-1 in vascular and renal disease. As will be evident, this peptide has emerged as a key target for drug therapy of hypertension and chronic kidney disease (CKD).
Endothelin in the control of blood pressure
ET-1 affects many systems that impact blood pressure (BP), including central and peripheral nerves, circulating hormones, the vasculature, the heart and the kidneys [1 ] . Vascular smooth muscle ETA and ETB activation causes vasoconstriction, whereas endothelial cell ETB activation is vasodilatory mainly due to nitric oxide release. ETB serves a clearance function; hence, ETB blockade raises plasma, and presumably tissue, ET-1 concentrations.
a Division of Nephrology, University of Utah Health Sciences Center and b Salt Lake Veterans Affairs Medical Center, Salt Lake City, Utah, USA ETB activation inhibits sodium transport in the nephron. The collecting duct endothelin system is particularly important; principal cells synthesize and bind unusually high levels of ET-1 [2] , while collecting duct-specific disruption of ET-1 causes salt-sensitive hypertension [3] . Recent studies indicate that the natriuretic and antihypertensive effect of collecting duct-derived ET-1 is partly mediated by nitric oxide [4] . Some perplexing findings relate to studies in mice with collecting ductspecific knockout of endothelin receptors. Collecting duct ETB knockout mice have salt-sensitive hypertension [5] , whereas collecting duct ETA knockout mice are normotensive [6] . However, collecting duct knockout of both ETA and ETB causes greater hypertension and sodium retention than in mice with only ETB disruption [7 ] . This suggests that, under certain circumstances, collecting duct ETA may exert a natriuretic effect. This conclusion is supported by recent studies in which renal medullary infusion of ET-1 into female rats lacking ETB increased urinary sodium excretion [8 ] . The mechanisms by which nephron ETA exerts a natriuretic effect are unknown; however, further clarification of this pathway is of clinical relevance. To my knowledge, every endothelin receptor antagonist used in humans and experimental animals, whether a combined ETA/ETB blocker or purportedly ETA-selective, causes hemodilution and edema, strongly suggestive of fluid retention [9] .
Indeed, such fluid retention may have been partly responsible for the failure of endothelin antagonists to benefit patients with congestive heart failure [1 ] . A recent, phase III trial studying the effect of avosentan (relatively ETA-selective) on renal function in patients with diabetic nephropathy was discontinued due to excessive fluid retention [10 ] . A follow-up study [11 ] determined that avosentan dose-dependently reduced urinary sodium excretion in normal individuals. Although it remains to be determined whether avosentan blocked ETB, particularly at the higher doses, the above results indicate that blocking renal ETB, and probably also ETA, reduces sodium excretion. Determining the mechanisms responsible for endothelin antagonist-induced fluid retention, and development of appropriate interventions, is clearly important to the future clinical utility of this class of drugs.
Endothelin in hypertension: preclinical studies
Numerous studies [1 ,12,13] in animals or humans have implicated endothelin in the pathogenesis and/or maintenance of hypertension (Figs 1 and 2 ). In the setting of hypertension, ET-1 increases vasoconstriction and promotes vascular remodeling. The increased vasoconstriction relates to elevated ET-1 production, neurohumoral Endothelin, hypertension and chronic kidney disease Kohan 135 ET-1, endothelin-1; IL-1, interleukin-1; LDL, low-density lipoproteins; PDGF, platelet-derived growth factor; ROS, reactive oxygen species; TGF-b, transforming growth factor beta; TNFa, tumor necrosis factor alpha; TxA2, thromboxane A2.
potentiation and/or downregulation of vasodilators such as nitric oxide. Both ETA and ETB have been implicated in the elevated vasoconstrictor response to ET-1 in hypertensive patients. Interestingly, ET-1-dependent vascular tone increases with aging, even in normotensive individuals (although the older patients had higher BP than younger ones); this effect was via ETA activation and could be reversed by regular aerobic exercise [14] . The enhanced role for ET-1 in vascular tone with aging may relate to the well documented increase in reactive oxygen species; ET-1 can increase, as well as be increased by, oxidative stress [15, 16] . In this regard, it is notable that plasma ET-1 levels inversely correlate with plasma antioxidant status in elderly individuals [17] .
Other findings suggest a role for ET-1 in uric acid and fructose feeding-associated hypertension. Rats fed a high-fructose diet developed hypertension that was ameliorated by bosentan, a nonselective endothelin receptor antagonist [18] ; bosentan also reduced plasma angiotensin II (AII) levels. Although the effect of targeting the endothelin system in uric acid-related hypertension has not been examined, in-vitro studies found that uric acid stimulates ET-1 gene expression in smooth muscle cells [19] and cardiomyocytes [20] . In keeping with the findings described above for aging, antioxidants suppressed uric acid-stimulated ET-1 synthesis by both cell types. Further, mutation of the activator protein 1 (AP-1) binding site in the ET-1 gene prevented uric acid induction of ET-1 production; this finding is consistent with the known effect of reactive oxygen species to activate jun and fos that bind AP-1 [20] .
Perhaps the greatest pathophysiological impact of ET-1 in hypertension relates to its effects on vascular remodeling. ET-1, via ETA activation, and in cooperation with AII, promotes vascular cell hypertrophy, hyperplasia, inflammatory cell infiltration and fibrosis. In animals, ETA or nonselective endothelin receptor blockade reduces atherosclerosis [1 ,12] . No long-term clinical trials have been conducted to date on the effect of endothelin antagonism on atherosclerosis; such studies will be of great importance.
Endothelin in hypertension: clinical trials
Only a few clinical trials have been completed using endothelin receptor blockade in systemic hypertension. The relative paucity of such trials relates, at least in part, to the side effect profile of this class of drugs [9] . First, ETA or ETB blockade is absolutely contraindicated in pregnancy due to teratogenic effects. Second, initial studies with bosentan were associated with hepatotoxicity, though modest (newer endothelin antagonists, particularly ETA blockers, do not appear to have this complication). Third, although the data have unfortunately never been . In addition, compared with placebo, atrasentan decreased fasting glucose, glycosylated hemoglobin, triglyceride, lipoprotein A and uric acid levels. In a subgroup not treated with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), atrasentan decreased serum creatinine concentration. Finally, no progression of angiographic coronary artery disease was detected in either atrasentan or placebo groups. Side effects were minimal; however, testicular toxicity was not assessed. Thus, endothelin blockers may fill an important clinical niche, particularly in patients with resistant hypertension, metabolic syndrome and atherosclerosis. No trials have compared ETA with nonselective endothelin receptor antagonists in such patients; however, the preclinical data suggest that ETA blockers hold the greatest promise in this regard.
Endothelin in chronic kidney disease: preclinical studies
Many studies [22 ,23 ,24] have demonstrated that the endothelin system is important in the pathophysiology of CKD (Figs 1 and 2) . First, renal ET-1 production is increased in virtually every form of CKD in humans and experimental animals. In hypertensive patients, plasma ET-1 also correlates with renal dysfunction [25] . Similarly, plasma ET-1 levels directly correlated with serum creatinine and degree of albuminuria in patients with diabetic nephropathy [26] . Second, as in the vasculature, ET-1 stimulates fibrosis, cell proliferation and inflammation in the kidney; the peptide can exert pathologic effects on every glomerular cell type and tubule cells. Third, endothelin receptor antagonists reduce renal injury and disease progression in multiple models of CKD, whether due to diabetes, autoimmune, high renin-dependent or mineralocorticoid-dependent hypertension, reduced renal mass and other causes.
Multiple mechanisms are responsible for elevated renal ET-1 production in CKD. Renal ET-1 synthesis is stimulated by cytokines, growth factors, chemokines, vasoactive factors, hormones, reactive oxygen species, cholesterol and other substances [22 ] (Fig. 1) . Protein overload stimulates proximal tubule ET-1 production, an event that may be of critical importance in renal disease progression [22 ,27] . In addition, ET-1 can induce nephrin loss from podocytes [28] , thereby potentially impairing slit diaphragm function. High dietary protein, through induction of metabolic acidosis, decreases glomerular filtration rate (GFR) in rats with reduced renal mass [29 ] . The high-protein diet caused primarily tubulointerstitial injury, a finding in keeping with the known effect of metabolic acidosis to induce nephron ET-1 production [30] . An interesting recent study [31] found that chromogranin A, which is released by sympathetic nerves and chromaffin cells, stimulates glomerular endothelial cell ET-1 release, which, in turn, enhanced transforming growth factor beta-1 (TGF-b1) production by mesangial cells. This group found that plasma chromogranin directly correlates with plasma ET-1 and inversely with GFR. Furthermore, a chromogranin promoter haplotype predicted the rate of GFR decline. Taken together, the above findings indicate that a truly impressive array of factors can enhance renal ET-1 production. As excessive renal ET-1 is clearly pathogenic in the kidney, it begs the question as to why the peptide is induced by so many different mechanisms. Although the reasons are not fully known, the very fact that ET-1 is produced by virtually every renal cell type, and that such synthesis can be under unique control in each cell type, sets the stage for this potent injurious peptide to be overproduced by a wide variety of conditions and stimuli.
Endothelin in chronic kidney disease: metabolic syndrome and diabetes ET-1 induced renal injury in the context of the metabolic syndrome, and diabetes deserves special mention. Insulin, whether in the setting of frank diabetes or insulin resistance, stimulates both the production and the action of ET-1 in experimental animals and/or in humans [32] . The insulin-stimulated ET-1 production is due, at least in part, to phosphoinositide-3-kinase-dependent activation of glycogen synthase-3b [33] . Insulin potentiation of ET-1 action was recently shown to involve an interaction with AII, as losartan blunted the enhanced ETAmediated vasoconstriction in insulin-treated diabetic rats [34] . Such an interaction with AII was highlighted in recent studies in diabetic rats, wherein renal damage actually regressed when avosentan and lisinopril were given together, but not separately [35 ] . These findings are further supported by the observation that endothelin antagonism reduced renal fibrosis in an animal model of severe AII-dependent hypertension [36] .
Endothelin in chronic kidney disease: clinical trials
No long-term studies have assessed the effect of endothelin antagonists on CKD progression. However, endothelin blockers have a substantial antiproteinuric effect. The Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease, and Death in Diabetic Nephropathy (ASCEND) trial, involving over 1300 patients, reported up to a 50% reduction in albuminuria after 3 or 6 months of avosentan therapy in patients with diabetic nephropathy on ACEI/ARB treatment [10 ] . Unfortunately, as discussed earlier, this trial was terminated due to fluid retention. A follow-up study [37 ] by this group involving 286 patients with diabetic nephropathy on ACEI/ARB therapy, using lower doses of avosentan, noted up to a 30% decrease in albuminuria after 12 weeks of treatment. A recent study [38 ] found that acute ETA blockade decreased proteinuria by about 30% in nondiabetic patients with CKD. BP was similarly lowered by nifedipine; however, this increased proteinuria by 26%. In keeping with the concept of an interaction with AII, a follow-up analysis by this group found that the magnitude of proteinuria reduction was greatest in patients on combined ACEI/ARB therapy [39] . Thus, although only proteinuria has been assessed to date, endothelin antagonism has exciting potential as a therapy in CKD.
Endothelin in chronic kidney disease: which receptor(s) to target?
Several studies have compared the effects of ETA-selective with combined ETA/ETB antagonists in various models of CKD, including hypertension, high dietary protein and reduced renal mass, as well as acutely in hypertensive patients with CKD [23 ] . In almost every instance, ETA, as compared with combined ETA/ETB, blockade has achieved superior results (GFR, fibrosis and/or proteinuria) [23 ,40] . Recent studies have supported these findings. Induction of diabetes in rats genetically deficient in ETB causes severe hypertension and progressive renal failure [41] . In a mouse model of polycystic kidney disease, ETB, but not ETA, antagonism accelerated the cystic kidney disease [42] ; notably, the ETB blocker effect was prevented by ETA antagonism. In high dietary protein-induced CKD in rats with reduced renal mass, ETA, but not combined ETA/ETB, antagonism prevented the reduction in GFR [29 ] . In a rat model of high AII hypertensive renal injury, ETA blockade reduced glomerular injury to a greater extent than did combined ETA/ETB antagonism [43] . All of these findings are in keeping with the known effect of ETA, but not ETB, to mediate vasoconstriction, cell injury and fibrosis in the kidney [22 ] . Thus, the available data support using ETA-selective antagonists in CKD. Having said that, it must be recognized that most of the studies are in experimental animals; until ETA-selective and combined ETA/ETB antagonists are compared in patients with CKD, this issue remains unresolved. Nonetheless, my own bias is that, at least in initial studies on CKD progression, ETA-selective blockers should be used.
Conclusion
ET-1 is an important pathogenic factor in hypertension, particularly in association with metabolic syndrome and/ or atherosclerosis. In addition, ET-1 plays a substantial role in CKD progression. Numerous preclinical, as well as the few completed clinical, studies suggest a substantial beneficial role for endothelin receptor antagonists, and particularly ETA blockers, in these disorders. However, in order to move forward, several key issues need to be addressed. First, the nature and mechanisms of endothelin antagonist-related adverse effects need elucidation. Second, appropriate doses of endothelin blockers need to be defined, including determination of the ones that are truly ETA-selective. Third, consideration must be given to which agents would best be coadministered with endothelin blockers. Finally, given the great promise of these drugs, the pharmaceutical industry and academia must work together to conduct long-term studies on cardiovascular and renal outcomes. 
